
Michael D. Burkhart
Examiner (ID: 3350, Phone: (571)272-2915 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1636, 1638, 1633 |
| Total Applications | 1174 |
| Issued Applications | 608 |
| Pending Applications | 127 |
| Abandoned Applications | 453 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17198749
[patent_doc_number] => 20210338843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => Co-Expression of Magnetotactic Bacterial Genes and Genes Encoding Iron Handling Proteins in Cells
[patent_app_type] => utility
[patent_app_number] => 17/376484
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376484
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/376484 | Co-Expression of Magnetotactic Bacterial Genes and Genes Encoding Iron Handling Proteins in Cells | Jul 14, 2021 | Abandoned |
Array
(
[id] => 19955448
[patent_doc_number] => 12325856
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-10
[patent_title] => Recombinant virus products and methods for inhibition of expression of myotilin
[patent_app_type] => utility
[patent_app_number] => 17/374147
[patent_app_country] => US
[patent_app_date] => 2021-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 19
[patent_no_of_words] => 6357
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17374147
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/374147 | Recombinant virus products and methods for inhibition of expression of myotilin | Jul 12, 2021 | Issued |
Array
(
[id] => 19164759
[patent_doc_number] => 11980641
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
[patent_app_type] => utility
[patent_app_number] => 17/366827
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 30
[patent_no_of_words] => 33460
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 137
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366827
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/366827 | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | Jul 1, 2021 | Issued |
Array
(
[id] => 17185496
[patent_doc_number] => 20210332381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => Ligand Matched Transcription Control, Control Devices, and Solute Carriers
[patent_app_type] => utility
[patent_app_number] => 17/365912
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25210
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365912
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/365912 | Ligand Matched Transcription Control, Control Devices, and Solute Carriers | Jun 30, 2021 | Pending |
Array
(
[id] => 17170344
[patent_doc_number] => 20210324014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => A NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS
[patent_app_type] => utility
[patent_app_number] => 17/357624
[patent_app_country] => US
[patent_app_date] => 2021-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22272
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357624
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/357624 | A NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS | Jun 23, 2021 | Abandoned |
Array
(
[id] => 19096431
[patent_doc_number] => 20240115658
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => Use of an intervertebral disc fibrosis-inducing substance in preparation of medication
[patent_app_type] => utility
[patent_app_number] => 18/029112
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029112
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/029112 | Use of an intervertebral disc fibrosis-inducing substance in preparation of medication | Jun 10, 2021 | Pending |
Array
(
[id] => 18146872
[patent_doc_number] => 20230020729
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING FC RECEPTOR-LIKE 5 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/332853
[patent_app_country] => US
[patent_app_date] => 2021-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59068
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332853
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/332853 | Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof | May 26, 2021 | Issued |
Array
(
[id] => 17095480
[patent_doc_number] => 20210283271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => RAAV WITH CHEMICALLY MODIFIED CAPSID
[patent_app_type] => utility
[patent_app_number] => 17/330902
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15212
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330902
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/330902 | rAAV with chemically modified capsid | May 25, 2021 | Issued |
Array
(
[id] => 18350645
[patent_doc_number] => 20230138756
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => ENGINEERED IMMUNE CELL AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/908109
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908109
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/908109 | Engineered immune cell and use thereof | May 23, 2021 | Issued |
Array
(
[id] => 17198692
[patent_doc_number] => 20210338786
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/306376
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31894
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306376
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/306376 | AADC polynucleotides for the treatment of Parkinson's disease | May 2, 2021 | Issued |
Array
(
[id] => 18552485
[patent_doc_number] => 20230250495
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => CAS9-BASED DIAGNOSTIC ASSAY AND METHODS OF USING
[patent_app_type] => utility
[patent_app_number] => 17/922633
[patent_app_country] => US
[patent_app_date] => 2021-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19532
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922633
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/922633 | CAS9-BASED DIAGNOSTIC ASSAY AND METHODS OF USING | Apr 30, 2021 | Pending |
Array
(
[id] => 18406066
[patent_doc_number] => 20230167417
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => MODEL-BASED CONTROL FOR COLUMN-BASED CONTINUOUS VIRAL INACTIVATION OF BIOPHARMACEUTICALS
[patent_app_type] => utility
[patent_app_number] => 17/997429
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10461
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997429
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/997429 | MODEL-BASED CONTROL FOR COLUMN-BASED CONTINUOUS VIRAL INACTIVATION OF BIOPHARMACEUTICALS | Apr 29, 2021 | Pending |
Array
(
[id] => 18420484
[patent_doc_number] => 20230174946
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => ORGAN INFECTION MODELS
[patent_app_type] => utility
[patent_app_number] => 17/922162
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32965
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922162
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/922162 | ORGAN INFECTION MODELS | Apr 29, 2021 | Abandoned |
Array
(
[id] => 18921847
[patent_doc_number] => 20240024851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => STRUCTURE, METHOD FOR PRODUCING SAME, ADSORBENT IN WHICH SAME IS USED, AND METHOD FOR PURIFYING BIOPARTICLES
[patent_app_type] => utility
[patent_app_number] => 17/997042
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18350
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997042
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/997042 | STRUCTURE, METHOD FOR PRODUCING SAME, ADSORBENT IN WHICH SAME IS USED, AND METHOD FOR PURIFYING BIOPARTICLES | Apr 26, 2021 | Abandoned |
Array
(
[id] => 20975046
[patent_doc_number] => 12735727
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-09-15
[patent_title] => Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity
[patent_app_type] => utility
[patent_app_number] => 17/921291
[patent_app_country] => US
[patent_app_date] => 2021-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 25
[patent_no_of_words] => 18989
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17921291
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/921291 | STABILIZATION OF POLYETHYLENEIMINE-DEOXYRIBONUCLEIC ACID COMPLEX SIZE AND ACTIVITY | Apr 25, 2021 | Pending |
Array
(
[id] => 18392585
[patent_doc_number] => 20230160804
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => Hematological Parameter for Viral Infection
[patent_app_type] => utility
[patent_app_number] => 17/920152
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5844
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920152
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/920152 | Hematological Parameter for Viral Infection | Apr 18, 2021 | Pending |
Array
(
[id] => 18071574
[patent_doc_number] => 11530398
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-20
[patent_title] => CRISPR-Cas effector polypeptides and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/229230
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 108
[patent_figures_cnt] => 96
[patent_no_of_words] => 87339
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17229230
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/229230 | CRISPR-Cas effector polypeptides and methods of use thereof | Apr 12, 2021 | Issued |
Array
(
[id] => 18675606
[patent_doc_number] => 20230313224
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => INTEGRATION OF LARGE ADENOVIRUS PAYLOADS
[patent_app_type] => utility
[patent_app_number] => 17/995671
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995671
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/995671 | INTEGRATION OF LARGE ADENOVIRUS PAYLOADS | Apr 11, 2021 | Pending |
Array
(
[id] => 17142014
[patent_doc_number] => 20210310026
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => METHODS AND COMPOSITIONS FOR EDITING RNAS
[patent_app_type] => utility
[patent_app_number] => 17/226961
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36125
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226961
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/226961 | METHODS AND COMPOSITIONS FOR EDITING RNAS | Apr 8, 2021 | Abandoned |
Array
(
[id] => 20207558
[patent_doc_number] => 20250277278
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-04
[patent_title] => QUALITATIVE AND QUANTITATIVE DETERMINATION OF SINGLE VIRUS HAPLOTYPES IN COMPLEX SAMPLES
[patent_app_type] => utility
[patent_app_number] => 17/911152
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16304
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911152
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/911152 | QUALITATIVE AND QUANTITATIVE DETERMINATION OF SINGLE VIRUS HAPLOTYPES IN COMPLEX SAMPLES | Apr 8, 2021 | Pending |